Physician profile
Nancy S Ling
NPI 1174586481
$2,735.32
in general payments reported to CMS, 2019-2025
27 companies · $703 in 2025
The $703 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $176 · 2021: $183 · 2022: $138 · 2023: $668 · 2024: $374 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.49 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $467.10 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Janssen Biotech, INC. | $403.09 | 2021-2025 | Tremfya |
| Organon LLC | $244.00 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $187.44 | 2021-2025 | Libtayo |
| Vyne Pharmaceuticals INC. | $163.09 | 2020-2021 | |
| Exact Sciences Corporation | $159.18 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $146.56 | 2019 | |
| Genentech USA, INC. | $132.27 | 2019 | |
| Organogenesis INC. | $122.80 | 2020-2024 | Puraply |
| Depuy Synthes Sales INC. | $119.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.27 | 2024-2025 | Spevigo |
| Covidien Lp | $58.14 | 2019 | |
| Sun Pharmaceutical Industries INC. | $54.45 | 2022-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $53.78 | 2022-2024 | Taltz |
| Almirall LLC | $46.89 | 2023-2025 | Klisyri, Seysara |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $44.60 | 2025 | |
| Amgen INC. | $29.90 | 2025 | Otezla |
| Pfizer INC. | $29.67 | 2020-2022 | |
| Surgenex LLC | $26.17 | 2025 | Ardeograft, Renograft, Surmatrix |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $25.49 | 2025 | |
| Dermira, INC. | $24.50 | 2021 | |
| Ani Pharmaceuticals, INC. | $23.15 | 2025 | Veregen |
| Sandoz INC. | $20.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.81 | 2022 | |
| Abbvie INC. | $18.81 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.89 | 2019 | |
| Galderma Laboratories, L.P. | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.